TRT Clinics Are Selling You Hormonal Chaos

The testosterone-to-IGF-1 pathway is one of the most misrepresented systems in men's health right now, and understanding how it actually works will explain why a lot of what TRT clinics are selling you is not optimization, it is manufactured demand.

Start with the full chain so you have the map.

Your body produces testosterone, and testosterone converts into estradiol through a process called aromatization, which is the enzymatic conversion of androgens into estrogens that happens in fat tissue, the liver, the brain, and elsewhere. That estradiol is not a side effect of testosterone. It is part of what testosterone is supposed to become, and it does specific jobs that testosterone alone cannot do.

One of those jobs is signaling the liver to produce something called IGF-1, which stands for insulin-like growth factor 1 and is the primary anabolic messenger your liver sends out after receiving hormonal instructions from growth hormone and estrogen. When estradiol is at healthy levels, the liver responds by producing more IGF-1. When estradiol drops, IGF-1 production drops with it. That relationship is direct and well-documented.

So the full chain looks like this: testosterone converts to estradiol, estradiol signals the liver, the liver produces IGF-1, and IGF-1 drives tissue repair, muscle protein synthesis, bone density, and recovery. Every link in that chain depends on the one before it.

Now here is where TRT clinics create the problem they later charge you to solve.

When a man starts testosterone therapy, his testosterone levels rise, and because aromatization scales with how much testosterone is available, his estradiol rises too. Many clinics treat rising estradiol as a problem by default, which is where a drug called anastrozole enters the picture. Anastrozole is an aromatase inhibitor, which is a compound that blocks the enzyme responsible for converting testosterone to estradiol. It was developed for post-menopausal women with estrogen-receptor-positive breast cancer, and it is extremely effective at dropping estradiol toward zero.

When a clinic gives you testosterone and then gives you anastrozole to control your estradiol, they are pressing the gas and the brake at the same time.

Your testosterone goes up. Your estradiol gets suppressed. And because estradiol is the signal the liver needs to produce IGF-1, your IGF-1 output falls. You may have more circulating testosterone than you have ever had, and yet feel worse in exactly the categories that testosterone is supposed to improve, because the downstream pathway that actually drives those effects has been cut off.

A man whose estradiol is sitting at 10 or 15 picograms per milliliter due to aggressive anastrozole use is not optimized. He is estrogen-deficient, and research on men with aromatase-deficiency disorders, which is a genetic condition where aromatization cannot occur, shows what that actually looks like. These men have normal or high testosterone, no functional estradiol, and they develop osteoporosis, impaired glucose metabolism, and poor lipid profiles despite the testosterone because so many of testosterone's downstream effects require estradiol as the intermediary.

The clinic now has a patient who feels fatigued and is not recovering well and has suboptimal IGF-1 levels, and their solution is to sell him IGF-1 directly.

This is where the business model reveals itself.

IGF-1 as a standalone prescription is indicated in genuine medical practice for a condition called primary IGF-1 deficiency due to growth hormone insensitivity, which is a situation where the pituitary produces growth hormone but the liver does not respond to it. This is rare enough that most physicians will never see a case in their career. It is not indicated for men who have suppressed their own estradiol with anastrozole and consequently lowered their own liver's IGF-1 output, because that is not a production problem. That is a signaling problem that was manufactured upstream.

Giving someone exogenous IGF-1 in that context does not fix the chain. It patches one symptom of a disruption that you are continuing to cause.

And it is expensive. Depending on the form and dose, IGF-1 peptides or secretagogues can add several hundred dollars per month to a protocol that was already charging for testosterone and anastrozole and monitoring visits. The patient's total spend keeps climbing because each intervention creates the need for the next one, and the root cause, which is the unnecessary suppression of estradiol, is never addressed.

The practical question is what to do instead.

The starting point is to stop treating estradiol as something to be minimized. In men, estradiol levels in the range of roughly 20 to 40 picograms per milliliter are associated with the best outcomes for bone density, libido, mood, and body composition. There are men who genuinely produce too much estradiol on testosterone and have symptoms from it, and in those specific cases anastrozole at a low and carefully titrated dose can be appropriate. But that is the exception, not the standing protocol for every man on TRT whose estradiol is measurably above the bottom of the reference range.

If your TRT clinic prescribes anastrozole as a routine part of every testosterone protocol rather than as a response to documented symptoms and lab values showing genuinely elevated estradiol, that is worth questioning directly.

And if that same clinic is recommending IGF-1 as an add-on to your testosterone protocol, ask them to walk you through why your liver is not producing adequate IGF-1 on its own, what is blocking the signal, and whether the anastrozole they also prescribed might be relevant to that question.

The answer to that last question tells you everything you need to know about whether they understand the system they are selling you.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness